NCT00813670

Single and Multiple Ascending Dose Safety Study of XPF-001 in Healthy Volunteers

Phase 1, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XPF-001 and to Investigate the Effect of Food on the Pharmacokinetics of a Single Dose of XPF-001 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 64 (estimated)
• Sponsor: Xenon Pharmaceuticals Inc. · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics of single and multiple doses of XPF-001 in healthy volunteers. The effect of food on the pharmacokinetics of XPF-001 will also be studied.

Conditions

• Healthy Human Volunteers

Interventions

Type	Name	Description
DRUG	XPF-001	Single oral dose, or 6 days of repeated oral doses.

Timeline

• Start date: 2008-11-01
• Primary completion: 2009-05-01
• Completion: 2009-07-01
• First posted: 2008-12-23
• Last updated: 2009-09-14

Locations

1 site across 1 country: Canada